Evidence map›Paper›PMID 38051056›Full record

ArticleMicrobiology spectrum2024

Influenza A virus infection alters the resistance profile of gut microbiota to clinically relevant antibiotics.

Marina Robas, Jesús Presa, Javier Arranz-Herrero, Soner Yildiz, Sergio Rius-Rocabert, Francisco Llinares-Pinel, Agustin Probanza, Mirco Schmolke, Pedro A Jiménez, Estanislao Nistal-Villan

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Marina Robas *Department of Pharmaceutical and Health Sciences School of Pharmacy, Microbiology Section, Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU , Madrid, Spain.
Jesús Presa *Department of Pharmaceutical and Health Sciences School of Pharmacy, Microbiology Section, Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU , Madrid, Spain.
Javier Arranz-HerreroDepartment of Pharmaceutical and Health Sciences School of Pharmacy, Microbiology Section, Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU , Madrid, Spain.
Soner YildizDepartment of Microbiology and Molecular Medicine, Medical Faculty, University of Geneva , Geneva, Switzerland.
Sergio Rius-RocabertDepartment of Pharmaceutical and Health Sciences School of Pharmacy, Microbiology Section, Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU , Madrid, Spain.
Francisco Llinares-PinelDepartment of Pharmaceutical and Health Sciences School of Pharmacy, Microbiology Section, Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU , Madrid, Spain.
Agustin ProbanzaDepartment of Pharmaceutical and Health Sciences School of Pharmacy, Microbiology Section, Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU , Madrid, Spain.
Mirco SchmolkeDepartment of Microbiology and Molecular Medicine, Medical Faculty, University of Geneva , Geneva, Switzerland.
Pedro A JiménezDepartment of Pharmaceutical and Health Sciences School of Pharmacy, Microbiology Section, Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU , Madrid, Spain.ORCID 0000-0003-0305-6889
Estanislao Nistal-VillanDepartment of Pharmaceutical and Health Sciences School of Pharmacy, Microbiology Section, Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU , Madrid, Spain.ORCID 0000-0003-2458-8833
Universidad San Pablo CEU · ESUniversity of Geneva · CH

Funding

Ministerio de Ciencia e Innovación (MCIN) project: PID2019-105761RB-100Swiss National Science Foundation (SNF) project: SNF310030_155949
6 · The paper itself

Abstract

importanceInfluenza virus infection affects both lung and intestinal bacterial community composition. Most of the published analyses focus on the characterization of the microbiota composition changes. Here we assess functional alterations of gut microbiota such as nutrient and antibiotic resistance changes during an acute respiratory tract infection. Upon influenza A virus (IAV) infection, cecal microbiota drops accompanied by a decrease in the ability to metabolize some common nutrients under aerobic conditions. At the same time, the cecal community presents an increase in resistance against clinically relevant antibiotics, particularly cephalosporins. Functional characterization of complex communities presents an additional and necessary element of analysis that nowadays is mainly limited to taxonomic description. The consequences of these functional alterations could affect treatment strategies, especially in multimicrobial infections.

Indexed as

Gastrointestinal MicrobiomeInfluenza A virusInfluenza, HumanOrthomyxoviridae InfectionsAnti-Bacterial AgentsHumansAnti-Bacterial Agentsantibiotic resistancecenoantibiograminfluenza virusintestinal microbiotamicrobial community

Identifiers

PMID38051056
PMCPMC10783141
OpenAlexW4389363096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.